Insmed Insider Sale: Brennan Offloads 25,000 Shares Amid Pipeline & Valuation Shake‑Up
Insmed insider sale: David Brennan sold 25,000 shares for $124 each, reflecting strategic liquidity moves amid a challenging biotech market and promising CF therapies like Sustair.
4 minutes to read